Successful ixazomib treatment for relapsed and refractory acute myeloid leukemia transformed from myelodysplastic syndrome | Zendy

Oka Satoko | Zendy; Ono Kazuo | Zendy

Open Access

Successful ixazomib treatment for relapsed and refractory acute myeloid leukemia transformed from myelodysplastic syndrome

Author(s) -

Oka Satoko,

Ono Kazuo

Publication year - 2021

Publication title -

clinical case reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.21

H-Index - 9

ISSN - 2050-0904

DOI - 10.1002/ccr3.4287

Subject(s) - medicine , azacitidine , ixazomib , myeloid leukemia , oncology , refractory (planetary science) , myelodysplastic syndromes , bone marrow , leukemia , bortezomib , myeloid , cancer research , multiple myeloma , carfilzomib , dna methylation , gene , physics , astrobiology , biochemistry , gene expression , chemistry

Elevated NF‐kB levels have been identified in primitive bone marrow cells from patients with MDS/AML, suggesting NF‐kB as a therapeutic target in MDS/AML. We herein describe an MDS patient ineligible for SCT who, following treatment with azacitidine and bortezomib, transformed to leukemia, but maintained complete remission after monotherapy with ixazomib.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research